Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceuticals said a combination of Copaxone and antibiotic minocycline reduced brain lesions in patients with relapsing-remitting multiple sclerosis, compared to receiving Copaxone alone.
Subscribe to our email newsletter
New data from a randomized, double-blind study showed that a combination of Copaxone with the oral antibiotic minocycline reduced T1 Gadolinium enhancing lesions of the brain by 63% and reduced the number of new T2 lesions in patients by 65%. These results trended toward but did not reach statistical significance.
Luanne Metz, professor at the Department of Clinical Neuroscience of the University of Calgary, and principal investigator, said: “The results of this study indicated that further exploration of this combination is warranted, as the established effect of Copaxone on disease activity may be boosted when used in combination with minocycline for the treatment of active relapsing-remitting patients.”